Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans

Marica Bordicchia, Ilaria Battistoni, Lucia Mancinelli, Elena Giannini, Giada Refi, Daniele Minardi, Giovanni Muzzonigro, Roberta Mazzucchelli, Rodolfo Montironi, Fabiana Piscitelli, Stefania Petrosino, Paolo Dessì-Fulgheri, Alessandro Rappelli, Vincenzo Di Marzo, Riccardo Sarzani

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Dysregulation of the endocannabinoid system in the visceral adipose tissue (VAT) is associated with metabolic and cardiovascular complications of obesity. We studied perirenal VAT CB1 receptor expression in relation to anthropometry, VAT area and endocannabinoid levels, kidney microvascular damage (MVDa), and the presence of the CB1 gene A3813G variant, the frequency of which was also evaluated in a large population of obese-hypertensive (OH) patients with or without the metabolic syndrome (MetS). Perirenal VAT and kidney samples were obtained from 30 patients undergoing renal surgery. Total and perirenal VAT areas were determined by computed tomography. CB1 messenger RNA expression and endocannabinoid levels in perirenal VAT were determined by quantitative reverse transcriptase polymerase chain reaction and liquid chromatography-mass spectrometry, respectively. The MVDa was evaluated in healthy portions of kidney cortex. The A3813G alleles were identified by genotyping in these patients and in 280 nondiabetic OH patients (age ≤65 years). Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Perirenal VAT CB1 expression was 40% lower in patients with the A3813G polymorphism, and correlated positively with perirenal and total VAT area and with perirenal VAT levels of the endocannabinoid anandamide. A 2-fold higher CB1 expression was associated with MVDa. The OH patients with the A3813G allele had lower prevalence of MetS in both unadjusted and adjusted models. Genetics influence perirenal VAT CB1 expression and the prevalence of MetS in OH. Increased VAT is associated with increased perirenal VAT endocannabinoid tone, which in turn correlates with increased MVDa. Endocannabinoid overactivity might be involved in human visceral obesity and its renal complications.

Original languageEnglish
Pages (from-to)734-741
Number of pages8
JournalMetabolism
Volume59
Issue number5
DOIs
Publication statusPublished - May 2010

Fingerprint

Cannabinoid Receptor CB1
Endocannabinoids
Intra-Abdominal Fat
Kidney
Alleles
Kidney Cortex
Anthropometry
Abdominal Obesity
Reverse Transcriptase Polymerase Chain Reaction
Liquid Chromatography
Mass Spectrometry

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. / Bordicchia, Marica; Battistoni, Ilaria; Mancinelli, Lucia; Giannini, Elena; Refi, Giada; Minardi, Daniele; Muzzonigro, Giovanni; Mazzucchelli, Roberta; Montironi, Rodolfo; Piscitelli, Fabiana; Petrosino, Stefania; Dessì-Fulgheri, Paolo; Rappelli, Alessandro; Di Marzo, Vincenzo; Sarzani, Riccardo.

In: Metabolism, Vol. 59, No. 5, 05.2010, p. 734-741.

Research output: Contribution to journalArticle

Bordicchia, M, Battistoni, I, Mancinelli, L, Giannini, E, Refi, G, Minardi, D, Muzzonigro, G, Mazzucchelli, R, Montironi, R, Piscitelli, F, Petrosino, S, Dessì-Fulgheri, P, Rappelli, A, Di Marzo, V & Sarzani, R 2010, 'Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans', Metabolism, vol. 59, no. 5, pp. 734-741. https://doi.org/10.1016/j.metabol.2009.09.018
Bordicchia, Marica ; Battistoni, Ilaria ; Mancinelli, Lucia ; Giannini, Elena ; Refi, Giada ; Minardi, Daniele ; Muzzonigro, Giovanni ; Mazzucchelli, Roberta ; Montironi, Rodolfo ; Piscitelli, Fabiana ; Petrosino, Stefania ; Dessì-Fulgheri, Paolo ; Rappelli, Alessandro ; Di Marzo, Vincenzo ; Sarzani, Riccardo. / Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. In: Metabolism. 2010 ; Vol. 59, No. 5. pp. 734-741.
@article{708e3369d8834f8f9967cb0ae6c155ae,
title = "Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans",
abstract = "Dysregulation of the endocannabinoid system in the visceral adipose tissue (VAT) is associated with metabolic and cardiovascular complications of obesity. We studied perirenal VAT CB1 receptor expression in relation to anthropometry, VAT area and endocannabinoid levels, kidney microvascular damage (MVDa), and the presence of the CB1 gene A3813G variant, the frequency of which was also evaluated in a large population of obese-hypertensive (OH) patients with or without the metabolic syndrome (MetS). Perirenal VAT and kidney samples were obtained from 30 patients undergoing renal surgery. Total and perirenal VAT areas were determined by computed tomography. CB1 messenger RNA expression and endocannabinoid levels in perirenal VAT were determined by quantitative reverse transcriptase polymerase chain reaction and liquid chromatography-mass spectrometry, respectively. The MVDa was evaluated in healthy portions of kidney cortex. The A3813G alleles were identified by genotyping in these patients and in 280 nondiabetic OH patients (age ≤65 years). Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Perirenal VAT CB1 expression was 40{\%} lower in patients with the A3813G polymorphism, and correlated positively with perirenal and total VAT area and with perirenal VAT levels of the endocannabinoid anandamide. A 2-fold higher CB1 expression was associated with MVDa. The OH patients with the A3813G allele had lower prevalence of MetS in both unadjusted and adjusted models. Genetics influence perirenal VAT CB1 expression and the prevalence of MetS in OH. Increased VAT is associated with increased perirenal VAT endocannabinoid tone, which in turn correlates with increased MVDa. Endocannabinoid overactivity might be involved in human visceral obesity and its renal complications.",
author = "Marica Bordicchia and Ilaria Battistoni and Lucia Mancinelli and Elena Giannini and Giada Refi and Daniele Minardi and Giovanni Muzzonigro and Roberta Mazzucchelli and Rodolfo Montironi and Fabiana Piscitelli and Stefania Petrosino and Paolo Dess{\`i}-Fulgheri and Alessandro Rappelli and {Di Marzo}, Vincenzo and Riccardo Sarzani",
year = "2010",
month = "5",
doi = "10.1016/j.metabol.2009.09.018",
language = "English",
volume = "59",
pages = "734--741",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans

AU - Bordicchia, Marica

AU - Battistoni, Ilaria

AU - Mancinelli, Lucia

AU - Giannini, Elena

AU - Refi, Giada

AU - Minardi, Daniele

AU - Muzzonigro, Giovanni

AU - Mazzucchelli, Roberta

AU - Montironi, Rodolfo

AU - Piscitelli, Fabiana

AU - Petrosino, Stefania

AU - Dessì-Fulgheri, Paolo

AU - Rappelli, Alessandro

AU - Di Marzo, Vincenzo

AU - Sarzani, Riccardo

PY - 2010/5

Y1 - 2010/5

N2 - Dysregulation of the endocannabinoid system in the visceral adipose tissue (VAT) is associated with metabolic and cardiovascular complications of obesity. We studied perirenal VAT CB1 receptor expression in relation to anthropometry, VAT area and endocannabinoid levels, kidney microvascular damage (MVDa), and the presence of the CB1 gene A3813G variant, the frequency of which was also evaluated in a large population of obese-hypertensive (OH) patients with or without the metabolic syndrome (MetS). Perirenal VAT and kidney samples were obtained from 30 patients undergoing renal surgery. Total and perirenal VAT areas were determined by computed tomography. CB1 messenger RNA expression and endocannabinoid levels in perirenal VAT were determined by quantitative reverse transcriptase polymerase chain reaction and liquid chromatography-mass spectrometry, respectively. The MVDa was evaluated in healthy portions of kidney cortex. The A3813G alleles were identified by genotyping in these patients and in 280 nondiabetic OH patients (age ≤65 years). Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Perirenal VAT CB1 expression was 40% lower in patients with the A3813G polymorphism, and correlated positively with perirenal and total VAT area and with perirenal VAT levels of the endocannabinoid anandamide. A 2-fold higher CB1 expression was associated with MVDa. The OH patients with the A3813G allele had lower prevalence of MetS in both unadjusted and adjusted models. Genetics influence perirenal VAT CB1 expression and the prevalence of MetS in OH. Increased VAT is associated with increased perirenal VAT endocannabinoid tone, which in turn correlates with increased MVDa. Endocannabinoid overactivity might be involved in human visceral obesity and its renal complications.

AB - Dysregulation of the endocannabinoid system in the visceral adipose tissue (VAT) is associated with metabolic and cardiovascular complications of obesity. We studied perirenal VAT CB1 receptor expression in relation to anthropometry, VAT area and endocannabinoid levels, kidney microvascular damage (MVDa), and the presence of the CB1 gene A3813G variant, the frequency of which was also evaluated in a large population of obese-hypertensive (OH) patients with or without the metabolic syndrome (MetS). Perirenal VAT and kidney samples were obtained from 30 patients undergoing renal surgery. Total and perirenal VAT areas were determined by computed tomography. CB1 messenger RNA expression and endocannabinoid levels in perirenal VAT were determined by quantitative reverse transcriptase polymerase chain reaction and liquid chromatography-mass spectrometry, respectively. The MVDa was evaluated in healthy portions of kidney cortex. The A3813G alleles were identified by genotyping in these patients and in 280 nondiabetic OH patients (age ≤65 years). Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Perirenal VAT CB1 expression was 40% lower in patients with the A3813G polymorphism, and correlated positively with perirenal and total VAT area and with perirenal VAT levels of the endocannabinoid anandamide. A 2-fold higher CB1 expression was associated with MVDa. The OH patients with the A3813G allele had lower prevalence of MetS in both unadjusted and adjusted models. Genetics influence perirenal VAT CB1 expression and the prevalence of MetS in OH. Increased VAT is associated with increased perirenal VAT endocannabinoid tone, which in turn correlates with increased MVDa. Endocannabinoid overactivity might be involved in human visceral obesity and its renal complications.

UR - http://www.scopus.com/inward/record.url?scp=77950624769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950624769&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2009.09.018

DO - 10.1016/j.metabol.2009.09.018

M3 - Article

C2 - 19919870

AN - SCOPUS:77950624769

VL - 59

SP - 734

EP - 741

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 5

ER -